For months, the conversation around GLP-1 medications like Ozempic, Wegovy and Mounjaro has revolved around one thing: they make people eat less
An engaged user is defined as a participant who completed the 24-week intervention and took any in-app action during the maintenance phase (weeks 24-65)
Schedule: Once-weekly subcutaneous injections with gradual titration for tolerability and consistent tracking
doi: 10.1056/NEJMoa2206038
Official Injection Sites for GLP-1 Medications According to their FDA-approved prescribing information, GLP-1 medications semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) are administered as injections just under the skin (subcutaneous) in three areas: Abdomen avoid the 2 inches (5 cm) directly around the navel Thigh outer/front thigh Upper arm back of the upper arm All four FDA labels (Ozempic 1 , Zepbound 2 , Mounjaro 3 , Wegovy 4 ) explicitly state that patients should rotate injection sites with each dose
Any compounded prescription requires a current patient-specific clinical and legal basis